Abstract: TH-PO1285
Proton Pump Inhibitor Use Is Associated with Improved Arteriovenous Fistula Patency in Patients with ESKD: A Retrospective Cohort Study with Experimental Support
Session Information
- Late-Breaking Research Posters
October 22, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Dialysis
- 803 Dialysis: Vascular Access
Authors
- Tu, Yuchi, Huazhong University of Science and Technology Tongji Medical College Union Hospital, Wuhan, Hubei, China
- Yao, Lijun, Huazhong University of Science and Technology Tongji Medical College Union Hospital, Wuhan, Hubei, China
Background
Pharmacological strategies to preserve arteriovenous fistula (AVF) patency in patients with end-stage kidney disease (ESKD) remain limited. The potential association between proton pump inhibitor (PPI) use and AVF outcomes remains unknown.
Methods
We retrospectively analyzed 107 patients with ESKD undergoing AVF creation, including 34 PPI users and 73 non-PPI users, with follow-up of up to 5 years. Baseline demographic, clinical, and laboratory characteristics were compared between the two groups. AVF patency was evaluated using Kaplan–Meier analysis, and Cox proportional hazards regression was performed to assess its association with PPI use. To support the clinical findings, the effect of lansoprazole on neointimal hyperplasia was evaluated in a murine model of CKD-associated AVF.
Results
Median AVF patency was longer in PPI users than in non-users (55 vs. 36 months), with a significant difference in Kaplan–Meier analysis (log-rank P=0.008). PPI use was significantly associated with AVF patency in both univariate (HR, 1.546; 95% CI, 1.026–2.329; P=0.033) and multivariable Cox regression analyses (HR, 1.585; 95% CI, 1.049–2.396; P=0.029). Consistent with the clinical findings, lansoprazole treatment significantly attenuated neointimal hyperplasia and improved AVF lumen dimensions in CKD-AVF mice.
Conclusion
PPI use was independently associated with longer AVF patency in patients with ESKD. Experimental evidence demonstrating that lansoprazole attenuated CKD-associated AVF neointimal hyperplasia.
Funding
- Government Support - Non-U.S.